Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicity
CONCLUSION: While there were geometric differences between the MDU and SUM, there was no clinically significant difference between urethral dose-volume parameters. This surrogate model could be validated in a larger cohort and then used to estimate the urethral dose on CT planning scans in those without an MRI planning scan or urinary catheter.PMID:38586079 | PMC:PMC10998036 | DOI:10.1016/j.ctro.2024.100769 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 8, 2024 Category: Cancer & Oncology Authors: Ragu Ratnakumaran Jonathan Mohajer Samuel J Withey Douglas H Brand Ernest Lee Andrew Loblaw Shaun Tolan Nicholas van As Alison C Tree PACE Trial Investigators Source Type: research
Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial
CONCLUSION: Daily online-adaptive MRgSBRT for localized prostate cancer resulted in an excellent overall toxicity profile without any major negative impact on quality of life.PMID:38586081 | PMC:PMC10998039 | DOI:10.1016/j.ctro.2024.100771 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 8, 2024 Category: Cancer & Oncology Authors: C A Fink J Ristau C Buchele S Kl üter J Liermann P Hoegen-Sa ßmannshausen E Sandrini A Lentz-Hommertgen L Baumann N Andratschke M Baumgartl M Li M Reiner S Corradini J H örner-Rieber D Bonekamp H-P Schlemmer C Belka M Guckenberger J Debus S A Koerber Source Type: research
Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer
CONCLUSIONS: PSMA and PSA mRNA expressions are associated with BCR in LPCa. In advanced prostate cancer, PSMA and PSA mRNA can also predict rapid progression from mHSPC to mCRPC and ARSI or taxane-based chemotherapy resistance.PMID:38587547 | DOI:10.1158/1078-0432.CCR-23-3083 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 8, 2024 Category: Cancer & Oncology Authors: Hyungseok Cho Seok-Soo Byun Nak-Hoon Son Jae Il Chung Won Ik Seo Chan Ho Lee Todd M Morgan Ki-Ho Han Jae-Seung Chung Source Type: research
Psoas mass index at the level of the third lumbar vertebra on computed tomography is a prognostic predictor for metastatic castration-sensitive prostate cancer
CONCLUSIONS: Pretreatment psoas muscle index is an independent predictor of poor castration-resistant prostate cancer-free survival and overall survival in patients with N1 and/or M1 metastatic castration-sensitive prostate cancer.PMID:38587577 | DOI:10.1007/s10147-024-02514-2 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 8, 2024 Category: Cancer & Oncology Authors: Shunsuke Owa Takeshi Sasaki Ryota Ikadai Yusaku Tabata Yushiro Takeuchi Taketomo Nishikawa Momoko Kato Shinichiro Higashi Yusuke Sugino Satoru Masui Kouhei Nishikawa Takahiro Inoue Source Type: research
Highlights in prostate cancer from the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
Clin Adv Hematol Oncol. 2024 Apr;22(3):112-113.NO ABSTRACTPMID:38588269 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 8, 2024 Category: Cancer & Oncology Source Type: research
Prostate Health Index (PHI) as a triage tool for reducing unnecessary magnetic resonance imaging (MRI) in patients at risk of prostate cancer
CONCLUSION: PHI could represent a reliable noninvasive tool for selecting patients to undergo mpMRI.PMID:38583655 | DOI:10.1016/j.clinbiochem.2024.110759 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 7, 2024 Category: Cancer & Oncology Authors: Luisa Agnello Matteo Vidali Giuseppe Salvaggio Francesco Agnello Bruna Lo Sasso Caterina Maria Gambino Marcello Ciaccio Source Type: research
Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials
CONCLUSION: The inclusion of ARAT agents was associated with a significantly higher risk of several CVAEs. Clinicians should remain vigilant, both in pre-treatment screening and monitoring for clinical symptoms and signs, when considering ARAT agent particularly for patients with pre-existing risk factors.PMID:38584004 | DOI:10.1016/j.clgc.2024.102066 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 7, 2024 Category: Cancer & Oncology Authors: Susu Zhou Parissa Alerasool Noriko Kishi Himanshu Joshi Gagan Sahni Che-Kai Tsao Source Type: research
High-dose-rate Brachytherapy Monotherapy in Patients With Localised Prostate Cancer: Dose Modelling and Optimisation Using Computer Algorithms
CONCLUSIONS: The RSM and ANN models determine almost the same optimal values for the set of predicted therapy parameters that make a feasible selection of an optimal treatment regime.PMID:38584072 | DOI:10.1016/j.clon.2024.03.009 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 7, 2024 Category: Cancer & Oncology Authors: K Dabic-Stankovic K Rajkovic J Stankovic G Marosevic G Kolarevic B Pavicar Source Type: research
Prostate Health Index (PHI) as a triage tool for reducing unnecessary magnetic resonance imaging (MRI) in patients at risk of prostate cancer
CONCLUSION: PHI could represent a reliable noninvasive tool for selecting patients to undergo mpMRI.PMID:38583655 | DOI:10.1016/j.clinbiochem.2024.110759 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 7, 2024 Category: Cancer & Oncology Authors: Luisa Agnello Matteo Vidali Giuseppe Salvaggio Francesco Agnello Bruna Lo Sasso Caterina Maria Gambino Marcello Ciaccio Source Type: research
Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials
CONCLUSION: The inclusion of ARAT agents was associated with a significantly higher risk of several CVAEs. Clinicians should remain vigilant, both in pre-treatment screening and monitoring for clinical symptoms and signs, when considering ARAT agent particularly for patients with pre-existing risk factors.PMID:38584004 | DOI:10.1016/j.clgc.2024.102066 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 7, 2024 Category: Cancer & Oncology Authors: Susu Zhou Parissa Alerasool Noriko Kishi Himanshu Joshi Gagan Sahni Che-Kai Tsao Source Type: research
High-dose-rate Brachytherapy Monotherapy in Patients With Localised Prostate Cancer: Dose Modelling and Optimisation Using Computer Algorithms
CONCLUSIONS: The RSM and ANN models determine almost the same optimal values for the set of predicted therapy parameters that make a feasible selection of an optimal treatment regime.PMID:38584072 | DOI:10.1016/j.clon.2024.03.009 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 7, 2024 Category: Cancer & Oncology Authors: K Dabic-Stankovic K Rajkovic J Stankovic G Marosevic G Kolarevic B Pavicar Source Type: research
Genomic ancestry and cancer among Latin Americans
Clin Transl Oncol. 2024 Apr 6. doi: 10.1007/s12094-024-03415-6. Online ahead of print.ABSTRACTLatin American populations, characterized by intricate admixture patterns resulting from the intermingling of ancestries from European, Native American (NA) Asian, and African ancestries which result in a vast and complex genetic landscape, harboring unique combinations of novel variants. This genetic diversity not only poses challenges in traditional population genetics methods but also opens avenues for a deeper understanding of its implications in health. In cancer, the interplay between genetic ancestry, lifestyle factors, and...
Source: Clinical Prostate Cancer - April 6, 2024 Category: Cancer & Oncology Authors: Alejandro Ru íz-Patiño Leonardo Rojas Jairo Zuluaga Oscar Arrieta Luis Corrales Claudio Mart ín Sandra Franco Luis Raez Christian Rolfo Natalia S ánchez Andr és Felipe Cardona Source Type: research
Head-to-head comparison of prostate-specific membrane antigen positron emission tomography/computed tomography and multiparametric magnetic resonance imaging in the detection of biochemical recurrence of prostate cancer: a systematic review and meta-analysis
CONCLUSION: The performance of PSMA PET/CT and mpMRI in identifying biochemical recurrence in PCa appears to be comparable. However, the meta-analysis' findings came from research with modest sample sizes. In this context, more extensive research should be conducted in the future.PMID:38582633 | DOI:10.1016/j.crad.2024.02.008 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 6, 2024 Category: Cancer & Oncology Authors: Z Jiang T Yang L Xu Source Type: research
Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis
CONCLUSIONS: Triplet therapy improves OS in mHSPC patients compared to docetaxel-based doublet therapy, irrespective of disease volume. However, based on treatment ranking, triplet therapy should preferably be considered for patients with high-volume mHSPC while those with low-volume are likely to be adequately treated with ARSI + ADT.PMID:38582807 | DOI:10.1007/s10147-024-02485-4 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 6, 2024 Category: Cancer & Oncology Authors: Akihiro Matsukawa Pawel Rajwa Tatsushi Kawada Kensuke Bekku Ekaterina Laukhtina Jakob Klemm Benjamin Pradere Keiichiro Mori Pierre I Karakiewicz Takahiro Kimura Piotr Chlosta Shahrokh F Shariat Takafumi Yanagisawa Source Type: research
Genomic ancestry and cancer among Latin Americans
Clin Transl Oncol. 2024 Apr 6. doi: 10.1007/s12094-024-03415-6. Online ahead of print.ABSTRACTLatin American populations, characterized by intricate admixture patterns resulting from the intermingling of ancestries from European, Native American (NA) Asian, and African ancestries which result in a vast and complex genetic landscape, harboring unique combinations of novel variants. This genetic diversity not only poses challenges in traditional population genetics methods but also opens avenues for a deeper understanding of its implications in health. In cancer, the interplay between genetic ancestry, lifestyle factors, and...
Source: Clinical Prostate Cancer - April 6, 2024 Category: Cancer & Oncology Authors: Alejandro Ru íz-Patiño Leonardo Rojas Jairo Zuluaga Oscar Arrieta Luis Corrales Claudio Mart ín Sandra Franco Luis Raez Christian Rolfo Natalia S ánchez Andr és Felipe Cardona Source Type: research
